Academic Bibliography

Search 200 years of publications by Ghent University researchers.

dr. Bram Van Den Eeckhout

No current affiliation with UGent

ORCID iD: 0000-0002-6729-8951

Add to list
- Journal Article
- A1
- open access
Rethinking IL-1 antagonism in respiratory viral infections : a role for IL-1 signaling in the development of antiviral T cell immunity

Bram Van Den Eeckhout (UGent) , Marlies Ballegeer (UGent) , Jozefien De Clercq (UGent) , Elianne Burg (UGent) , Xavier Saelens (UGent) , Linos Vandekerckhove (UGent) and Sarah Gerlo (UGent)

(2023) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 24(21).
Add to list
- Journal Article
- A1
- open access
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Sandra Van Lint (UGent) , Alexander Van Parys (UGent) , Bram Van Den Eeckhout (UGent) , Niels Vandamme (UGent) , Stephane Plaisance, Annick Verhee (UGent) , Dominiek Catteeuw (UGent) , Elke Rogge (UGent) , Jennifer De Geest (UGent) , Nele Vanderroost (UGent) , et al.

(2023) MOLECULAR CANCER. 22(1).
Add to list
- Journal Article
- A1
- open access
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Elke Rogge, Annick Verhee (UGent) , Bram Van Den Eeckhout (UGent) , Shengru Pang, Marco Prinz, Niko Kley, Gilles Uze and Jan Tavernier (UGent)

(2021) SCIENTIFIC REPORTS. 11(1).
Add to list
- Journal Article
- A1
- open access
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Bram Van Den Eeckhout (UGent) , Leander Huyghe (UGent) , Sandra Van Lint (UGent) , Elianne Burg (UGent) , Stéphane Plaisance, Frank Peelman (UGent) , Anje Cauwels (UGent) , Gilles Uzé, Niko Kley, Sarah Gerlo (UGent) , et al.

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9(11).
Add to list
- Journal Article
- A1
- open access
Interleukin-1 as innate mediator of T cell immunity

Bram Van Den Eeckhout (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2021) FRONTIERS IN IMMUNOLOGY. 11.
Add to list
- PhD Thesis
Development of IL-1β AcTakines : towards new adjuvants in vaccination strategies

Bram Van Den Eeckhout (UGent)

(2021)
Add to list
- Journal Article
- A1
- open access
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) NPJ VACCINES. 5(1).
Add to list
- Conference Paper
- C3
Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) T Cell Memory, Abstracts.
Add to list
- Conference Paper
- C3
Towards the use of interleukin-1β as vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2019) The 1918 influenza pandemic: historical and biomedical reflections, VIB conference, Abstracts.
Add to list
- Conference Paper
- C3
IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den Eeckhout (UGent) , Elianne Burg (UGent) , Anje Cauwels (UGent) , Frank Peelman (UGent) , Sandra Van Lint (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2018) Dendritic Cells, 15th International symposium, Abstracts.

1
2

Next →